– UK, Watford – Smith+Nephew (LON: SN / NYSE: SNN), the global medical technology company, announced the appointment of Thérèse Esperdy to its Board as an independent Non-Executive Director and Senior Independent Director designate with effect from 1 December 2025. She will succeed Angie Risley as Senior Independent Director following the Company’s AGM in May 2026.
About Thérèse Esperdy
Thérèse Esperdy is the non-executive chair of Imperial Brands plc and a non-executive director of Moody’s Corporation and was previously senior independent director of National Grid plc. In her executive career, Thérèse held senior leadership roles at JPMorgan, including global chair of their Financial Institutions Group, co-head of Asia-Pacific Corporate & Investment Banking, and global head of Debt Capital Markets.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & EN, T, and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more: https://www.smith-nephew.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.